Macrocyclic Peptides Designed to Trap Bacterial DNA Junctions as Novel Antibiotics
Eight macrocyclic peptides designed to bind Holliday junctions (DNA recombination intermediates) in bacteria showed antibacterial activity, introducing an entirely new antibiotic mechanism targeting bacterial DNA repair.
Quick Facts
What This Study Found
Macrocyclic peptides designed to bind Holliday DNA junctions showed antibacterial activity, validating a completely novel antibiotic mechanism targeting bacterial DNA repair/recombination.
Key Numbers
How They Did This
In-vitro study. Eight macrocyclic peptides designed computationally to bind Holliday junction DNA structures. Synthesized and tested for antibacterial activity against bacterial cultures.
Why This Research Matters
A completely new antibiotic mechanism — targeting DNA junctions — gives bacteria no pre-existing resistance. Novel mechanisms are desperately needed as existing antibiotic classes fail.
The Bigger Picture
Every new antibiotic mechanism represents a new weapon against resistance. Targeting DNA recombination is fundamentally different from membrane disruption, ribosome inhibition, or cell wall synthesis — the targets of existing antibiotics.
What This Study Doesn't Tell Us
Short abstract with limited potency data. In-vivo efficacy unknown. Selectivity for bacterial versus human DNA junctions needs confirmation.
Questions This Raises
- ?Do these peptides selectively target bacterial Holliday junctions?
- ?Can the potency be improved through structural optimization?
- ?Would bacteria develop resistance to DNA junction trapping?
Trust & Context
- Key Stat:
- Brand new mechanism These macrocyclic peptides target bacterial DNA junctions — a mechanism no existing antibiotic uses, meaning no pre-existing resistance exists
- Evidence Grade:
- Preliminary in-vitro proof-of-concept with novel mechanism validation, limited by early-stage development.
- Study Age:
- Published in 2003. DNA-targeting antimicrobial strategies continue to be explored as novel antibiotic approaches.
- Original Title:
- Novel antibiotics: macrocyclic peptides designed to trap Holliday junctions.
- Published In:
- Organic letters, 5(2), 109-12 (2003)
- Authors:
- Bolla, Megan L, Azevedo, Enrique V, Smith, Jason M, Taylor, Rachel E, Ranjit, Dev K, Segall, Anca M, McAlpine, Shelli R
- Database ID:
- RPEP-00796
Evidence Hierarchy
Frequently Asked Questions
How are these different from other antibiotics?
Most antibiotics target bacterial protein production, cell walls, or membranes. These target bacterial DNA repair — a completely different mechanism that bacteria have never encountered as an antibiotic target.
Could bacteria resist this?
Resistance to a DNA junction-trapping mechanism would require bacteria to fundamentally change their DNA repair system — much harder than evolving resistance to conventional antibiotics.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00796APA
Bolla, Megan L; Azevedo, Enrique V; Smith, Jason M; Taylor, Rachel E; Ranjit, Dev K; Segall, Anca M; McAlpine, Shelli R. (2003). Novel antibiotics: macrocyclic peptides designed to trap Holliday junctions.. Organic letters, 5(2), 109-12.
MLA
Bolla, Megan L, et al. "Novel antibiotics: macrocyclic peptides designed to trap Holliday junctions.." Organic letters, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Novel antibiotics: macrocyclic peptides designed to trap Hol..." RPEP-00796. Retrieved from https://rethinkpeptides.com/research/bolla-2003-novel-antibiotics-macrocyclic-peptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.